Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Sees Significant Decline in Short Interest

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) was the recipient of a large decrease in short interest in the month of December. As of December 31st, there was short interest totalling 600,700 shares, a decrease of 51.9% from the December 15th total of 1,250,000 shares. Currently, 7.3% of the company’s stock are sold short. Based on an average trading volume of 4,890,000 shares, the short-interest ratio is currently 0.1 days.

Shares of CPIX opened at $3.99 on Friday. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.63 and a quick ratio of 2.06. The business’s 50 day moving average price is $3.98 and its 200-day moving average price is $3.27. Cumberland Pharmaceuticals has a 52 week low of $2.20 and a 52 week high of $7.51.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last issued its quarterly earnings results on Tuesday, November 9th. The specialty pharmaceutical company reported ($0.03) EPS for the quarter. The company had revenue of $8.07 million during the quarter. Cumberland Pharmaceuticals had a positive return on equity of 0.37% and a negative net margin of 1.43%.

A number of hedge funds have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP lifted its holdings in shares of Cumberland Pharmaceuticals by 2.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 755,500 shares of the specialty pharmaceutical company’s stock valued at $2,149,000 after buying an additional 17,619 shares during the period. Citadel Advisors LLC purchased a new stake in shares of Cumberland Pharmaceuticals in the 3rd quarter worth $32,000. Morgan Stanley increased its stake in shares of Cumberland Pharmaceuticals by 131.3% in the 1st quarter. Morgan Stanley now owns 11,160 shares of the specialty pharmaceutical company’s stock worth $34,000 after purchasing an additional 6,335 shares in the last quarter. Finally, Berkshire Asset Management LLC PA increased its stake in shares of Cumberland Pharmaceuticals by 3.1% in the 3rd quarter. Berkshire Asset Management LLC PA now owns 176,185 shares of the specialty pharmaceutical company’s stock worth $472,000 after purchasing an additional 5,355 shares in the last quarter. 18.69% of the stock is currently owned by institutional investors and hedge funds.

Separately, TheStreet upgraded Cumberland Pharmaceuticals from a “d” rating to a “c-” rating in a report on Monday, December 6th.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals, Inc is a specialty pharmaceutical company, which engages in the acquisition, development, and commercialization of prescription products. Its product include Acetadote, Caldolor, Kristalose, Omeclamox, Vaprisol, Vibativ, and RediTrex. The company was founded by A. J. Kazimi on January 6, 1999 and is headquartered in Nashville, TN.

Featured Article: Stock Split

Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.